The global cancer diagnostics market is undergoing significant transformation driven by advancements in technology, increasing cancer prevalence, and the growing demand for early detection tools. Healthcare systems worldwide are placing stronger emphasis on preventive care and timely diagnosis, which is fueling the adoption of innovative diagnostic methods. Emerging economies are witnessing rising healthcare expenditure and infrastructure development, enabling broader access to cancer diagnostic services. Additionally, collaborations between research institutions, diagnostic companies, and healthcare providers are enhancing the speed and accuracy of cancer detection.
Global Cancer Diagnostics Market size was valued at USD 21.6 billion in 2023 and is poised to grow from USD 23.63 billion in 2024 to USD 48.49 billion by 2032, growing at a CAGR of 9.4% during the forecast period (2025-2032).
The market is driven by the increasing global burden of cancer, necessitating more efficient and accurate diagnostic methods. Technological innovations, including liquid biopsy, next-generation sequencing, and AI-powered imaging tools, are enhancing diagnostic capabilities and expanding their applications. Rising demand for personalized medicine is also pushing the adoption of advanced molecular diagnostics that can identify specific cancer biomarkers.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/cancer-diagnostics-market
Cancer Diagnostics Market – Regional Analysis:
North America leads the global cancer diagnostics market, propelled by advanced healthcare infrastructure, significant R&D investments, and a high prevalence of cancer. The U.S. commands the largest share in North America’s cancer diagnostics market, driven by increasing awareness programs, a high prevalence of cancer, and a favorable reimbursement and regulatory landscape that adapts to rapid research progress. Canada’s cancer diagnostics market benefits from robust research institutions like the Ontario Institute for Cancer Research (OICR), which hosts resources such as the Ontario Tumor Bank and the Canadian Cancer Clinical Trials Network.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Cancer Diagnostics Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
The Global Cancer Diagnostics Market is segmented by Product Type, Technology, Application, End-User Industry and region.
Based on Product Type, the market is segmented into Consumables and Instruments.
Based on Technology, the market is segmented into IVD Testing, Imaging and Biopsy Technique.
Based on Application, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma and Other Cancers.
Based on End-User Industry, the market is segmented into Hospitals, Diagnostic Laboratories and Others.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Top Market Players in Cancer Diagnostics Market are:
Abbott Laboratories (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Siemens Healthineers (Germany)
Thermo Fisher Scientific Inc. (USA)
GE Healthcare (USA)
Hologic Inc. (USA)
Illumina Inc. (USA)
Bio-Rad Laboratories Inc. (USA)
Agilent Technologies Inc. (USA)
bioMérieux SA (France)
Myriad Genetics Inc. (USA)
Qiagen N.V. (Netherlands)
PerkinElmer Inc. (USA)
Danaher Corporation (USA)
Recent Developments in Cancer Diagnostics Market:
In May 2025, Telangana has initiated a groundbreaking healthcare revamp by integrating artificial intelligence (AI) into cancer screening processes. The state will pilot AI-based screening in three districts, focusing on oral, breast, and cervical cancers. High-resolution imaging and AI algorithms will be used to detect abnormalities, which will then be referred for specialist evaluation. The MNJ Cancer Institute is leading the software development for this initiative.
In February 2025, Guardant Health experienced a significant stock surge after Medicare agreed to cover its colon cancer blood test, Guardant Reveal. This test detects recurrent cancer early by analyzing tumor DNA in a patient’s blood and was previously covered only for patients undergoing adjuvant therapy. The expanded reimbursement significantly broadens Guardant Health’s potential market reach.
In September 2024, Siemens Healthineers has secured a deal to purchase part of Novartis’s Advanced Accelerator Applications (AAA) business for over €200 million. This acquisition bolsters Siemens’ PET radiopharmaceutical business by supplying critical radioactive chemicals for cancer scans, enabling expansion in Europe.
You may Also Like
https://sites.google.com/view/insightdigits/activated-carbon-market
Forward-Looking Insights
The Cancer Diagnostics Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]”””
